Kamada Ltd. (NASDAQ:KMDA) was the target of a large growth in short interest in September. As of September 15th, there was short interest totalling 542,300 shares, a growth of 20.7% from the August 31st total of 449,300 shares. Currently, 2.2% of the company’s stock are sold short. Based on an average daily trading volume, of 485,500 shares, the days-to-cover ratio is presently 1.1 days.
Institutional investors have recently modified their holdings of the business. Phoenix Holdings Ltd. lifted its stake in shares of Kamada by 2.8% during the first quarter. Phoenix Holdings Ltd. now owns 1,033,092 shares of the biotechnology company’s stock worth $5,884,000 after buying an additional 28,524 shares during the period. Atom Investors LP acquired a new position in shares of Kamada during the second quarter worth $776,000. UBS Group AG increased its holdings in Kamada by 20.1% in the second quarter. UBS Group AG now owns 89,595 shares of the biotechnology company’s stock valued at $695,000 after buying an additional 14,969 shares during the last quarter. ETF Managers Group LLC raised its stake in Kamada by 9.7% in the first quarter. ETF Managers Group LLC now owns 49,399 shares of the biotechnology company’s stock valued at $278,000 after buying an additional 4,388 shares in the last quarter. Finally, James Investment Research Inc. lifted its holdings in Kamada by 10.8% during the 2nd quarter. James Investment Research Inc. now owns 48,460 shares of the biotechnology company’s stock worth $376,000 after buying an additional 4,705 shares during the last quarter. Institutional investors and hedge funds own 14.02% of the company’s stock.
KMDA has been the subject of several recent research reports. Zacks Investment Research downgraded Kamada from a “buy” rating to a “hold” rating in a report on Tuesday, June 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Kamada in a research report on Thursday, August 13th. ValuEngine upgraded shares of Kamada from a “sell” rating to a “hold” rating in a research note on Monday, August 3rd. Chardan Capital upped their target price on Kamada from $7.00 to $11.00 and gave the stock a “buy” rating in a report on Friday, August 14th. Finally, BidaskClub cut Kamada from a “hold” rating to a “sell” rating in a research report on Saturday, September 5th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $10.33.
Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported $0.08 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.12 by ($0.04). Kamada had a return on equity of 13.22% and a net margin of 15.10%. The business had revenue of $33.09 million during the quarter, compared to analyst estimates of $34.61 million. Equities analysts forecast that Kamada will post 0.36 EPS for the current year.
Kamada Company Profile
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency.
Further Reading: Buy-Side Analysts
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.